PRQR vs SNY
ProQR Therapeutics N.v. and Sanofi, side by side — 5 fiscal years reported in EUR, drawn from SEC filings.
Most recent reported year
| Metric | PRQR | SNY |
|---|---|---|
| Revenue | €15.9M | €43.6B |
| Net income | €-42.2M | €7.8B |
| Gross margin | · | 77.2% |
| Net margin | −265.2% | 18.0% |
| Return on equity | −61.2% | 10.5% |
| Diluted EPS | −€0.40 | €6.37 |
| Dividend / share | · | €3.92 |
| Payout ratio | · | 61.1% |
| Free cash flow | €-53.8M | · |
| Equity | €49.4M | €71.4B |
| Net debt / equity | −1.77× | 0.15× |
| Current ratio | 3.09× | 1.09× |
| Revenue CAGR 5y | · | 3.9% |
| Profit CAGR 5y | · | −8.7% |
SNY bills 2742.7× the revenue of PRQR, and PRQR closed the last reported year at a loss.
The stronger figure of the pair is set in bold. That is arithmetic, not a recommendation — this page does not pick a winner. "·" marks a figure not available in our data.
5 years side by side
| Fiscal year | PRQR | SNY |
|---|---|---|
| FY2025 | €15.9M | €43.6B |
| FY2024 | €18.9M | €41.1B |
| FY2023 | €6.5M | €37.8B |
| FY2022 | €3.6M | €37.7B |
| FY2021 | €1.3M | €37.8B |
Bottom line
| Fiscal year | PRQR | SNY |
|---|---|---|
| FY2025 | €-42.2M | €7.8B |
| FY2024 | €-27.8M | €5.6B |
| FY2023 | €-28.1M | €5.4B |
| FY2022 | €-64.4M | €8.4B |
| FY2021 | €-60.7M | €6.2B |
5 fiscal years
| Fiscal year | Difference | Ahead |
|---|---|---|
| FY2025 | −€43,610,094,000 | SNY |
| FY2024 | −€41,062,095,000 | SNY |
| FY2023 | −€37,810,486,000 | SNY |
| FY2022 | −€37,647,406,000 | SNY |
| FY2021 | −€37,759,665,000 | SNY |
SNY has reported the higher revenue in every one of these 5 fiscal years. The gap has widened since the earliest year compared.
5 of 11 comparable fiscal years — a year missing data on either side is not counted.
Standard deviation, each side
PRQR's net margin has been more volatile than SNY's over the 3 comparable fiscal years — 114.3 percentage points of standard deviation against 1.9.
3 of 11 comparable fiscal years — a year missing data on either side is not counted.
Year by year
SNY led in net margin in every one of the 3 comparable fiscal years — a structural lead, not a recent swing.
3 of 11 comparable fiscal years — a year missing data on either side is not counted.
Standard deviation, each side
PRQR's return on equity has been more volatile than SNY's over the 11 comparable fiscal years — 17.0 percentage points of standard deviation against 4.1.
11 of 11 comparable fiscal years — a year missing data on either side is not counted.
Year by year
SNY led in return on equity in every one of the 11 comparable fiscal years — a structural lead, not a recent swing.
11 of 11 comparable fiscal years — a year missing data on either side is not counted.